Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $118.15 | Total: $590.75 |
| 1 | 10 | $100.08 | Total: $1,000.80 |
| 1 | 25 | $84.79 | Total: $2,119.75 |
| 1 | 50 | $72.28 | Total: $3,614.00 |
| 1 | 100 | $62.55 | Total: $6,255.00 |
Overview
ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2ALX internalization into monocytes. It has the potential for the treatment of inflammatory disorders.
Chemical Properties
| Molecular Formula | C20H18F2N6O3 |
| Molecular Weight | 428.39 |
| CAS Numbers | 1258417-54-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Cc1nc(C(=O)Nc2cnn(Cc3nc(co3)C(C)(F)F)n2)c(o1)-c1cccc(C)c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Stalder AK,et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83[3] 476-486.